Physician profile
Matthew Seto
NPI 1003163486
$11,133.96
in general payments reported to CMS, 2019-2025
37 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $1,006 · 2021: $1,165 · 2022: $1,478 · 2023: $1,718 · 2024: $2,161 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263 · Grant: $335 · Education: $62.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.11 |
| Grant | $335.00 |
| Education | $62.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,083.14 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Gilead Sciences, INC. | $1,402.12 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,208.98 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $971.75 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $505.04 | 2021-2024 | Zeposia |
| Pfizer INC. | $475.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $368.19 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $362.68 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Boston Scientific Corporation | $339.26 | 2019-2023 | Spyglass |
| Ardelyx, INC. | $279.83 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $274.52 | 2022-2025 | |
| Qol Medical, LLC | $215.84 | 2019-2024 | Sucraid |
| Lilly USA, LLC | $204.34 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $202.03 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $200.82 | 2019-2025 | Ocaliva |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $117.01 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $112.02 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $94.83 | 2024-2025 | Zenpep, Vowst |
| Fresenius Kabi USA, LLC | $91.69 | 2023-2024 | Idacio |
| Celltrion USA INC. | $89.10 | 2023-2024 | Yuflyma, Vegzelma, Zymfentra |
| Ucb, INC. | $74.48 | 2019-2020 | |
| Redhill Biopharma INC. | $68.49 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $68.00 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $66.03 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $55.54 | 2022-2023 | Rebyota |
| Sandoz INC. | $26.19 | 2025 | Hyrimoz |
| Ethicon US, LLC | $22.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.17 | 2022 | |
| Daiichi Sankyo INC. | $18.00 | 2019 | |
| Shire North American Group INC | $16.63 | 2019 | |
| Novo Nordisk INC | $16.52 | 2025 | Wegovy |
| Allergan, INC. | $15.86 | 2020 | |
| Organon LLC | $14.25 | 2023 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $14.10 | 2022 | |
| Alfasigma USA, INC. | $13.42 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $12.13 | 2024 | |
| Shionogi INC | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Seto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.